MoonLake Immunotherapeutics(US:MLTX) Globenewswire·2025-11-24 20:01Core Viewpoint - The Gross Law Firm is notifying shareholders of MoonLake Immunotherapeutics (NASDAQ: MLTX) about a class action lawsuit due to alleged misleading statements regarding the company's drug candidate SLK and its comparison to BIMZELX [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from March 10, 2024, to September 29, 2025 [3]. - Allegations include that the defendants made materially false statements and failed to disclose critical information about SLK's clinical efficacy compared to BIMZELX [3]. Allegations Against the Company - The complaint states that SLK and BIMZELX target the same inflammatory cytokines IL-17A and IL-17F [3]. - It is claimed that SLK's unique Nanobody structure does not provide a clinical benefit over the traditional monoclonal structure of BIMZELX [3]. - The supposed increased tissue penetration of SLK is alleged not to translate into clinical efficacy [3]. - Defendants are accused of lacking a reasonable basis for their positive statements regarding SLK's superiority to monoclonal antibodies [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].